XBiotech Inc (OQ:XBIT)

Sep 21, 2020 08:20 am ET
XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections
XBiotech Inc. (NASDAQ: XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by combined infections with influenza and COVID-19. With the global spread of the novel COVID-19 virus,...
Aug 24, 2020 08:10 am ET
XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization
XBiotech Inc. (NASDAQ: XBIT) announced today that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for COVID-19 Convalescent Plasma (CCP) as a COVID-19 treatment, opening the door for XBiotech’s antibody...
Aug 17, 2020 08:20 am ET
XBiotech Discovers COVID-19 Candidate Therapy
XBiotech Inc. (NASDAQ: XBIT) announced today that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2, the virus that causes COVID-19. The Company discovered these antibodies through a collaboration...
Jul 22, 2020 09:20 am ET
XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy
XBiotech Inc. (NASDAQ: XBIT) announced today it has achieved a crucial milestone in the development of its next generation inflammation-fighting True Human antibodies. The Company is developing a new antibody to replace a previous generation True...
Jul 14, 2020 09:25 am ET
XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke
XBiotech Inc. (NASDAQ: XBIT) announced today findings published in the prestigious American Heart Association’s journal, Circulation. The publication titled, Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and...
May 01, 2020 09:25 am ET
XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy
XBiotech Inc. (NASDAQ: XBIT) announced today that human immune donors have now been identified that can support the Company’s development of a True Human™ antibody therapy for COVID-19. XBiotech recently developed and transferred screening...
Apr 14, 2020 09:15 am ET
XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺)
XBiotech Inc. (NASDAQ: XBIT) announced today that a novel antibody it has discovered that neutralizes interleukin-1 alpha (IL-1⍺) has now been advanced as a product candidate for clinical and commercial development. XBiotech discovered the IgG1...
Apr 03, 2020 04:53 pm ET
XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration (FDA) investigational program for U.S. blood centers to begin collecting and distributing convalescent...
Feb 19, 2020 08:15 am ET
XBiotech Announces Final Results of Tender Offer
XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the final count by American Stock Transfer &...
Feb 13, 2020 01:24 pm ET
Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer
This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor.  The corrected press release reads: XBiotech Announces Preliminary Results of Tender Offer XBiotech Inc....
Feb 13, 2020 08:15 am ET
XBiotech Announces Preliminary Results of Tender Offer
XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the preliminary count by American Stock...
Jan 14, 2020 08:30 am ET
XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares
XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly tendered and not...
Dec 30, 2019 04:05 pm ET
XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen
XBiotech Inc. (NASDAQ: XBIT) announced today closing of the sale of the Company’s True Human antibody Bermekimab to Janssen Biotech, Inc. (Janssen), a Janssen Pharmaceutical Company of Johnson & Johnson. Upon closing, Janssen paid XBiotech $750...
Dec 17, 2019 08:15 am ET
XBiotech Added to NASDAQ Biotechnology Index
XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will become effective prior to market open on Monday, December 23, 2019. The Index is...
Dec 07, 2019 03:05 am ET
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen
XBiotech Inc. (NASDAQ: XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, to sell XBiotech’s novel antibody (bermekimab) that neutralizes...
Dec 07, 2019 03:05 am ET
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen
XBiotech Inc. (NASDAQ: XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, to sell XBiotech’s novel antibody (bermekimab) that neutralizes...
Nov 19, 2019 08:55 am ET
XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa
XBiotech Inc. (NASDAQ: XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). The study is chaired...
Nov 12, 2019 08:45 am ET
XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1⍺ Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)
XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking antibody therapy in patients with moderate to severe Atopic Dermatitis (AD) (also...
Oct 23, 2019 08:15 am ET
XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa
XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). The...
Oct 02, 2019 08:59 am ET
XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis
XBiotech (NASDAQ: XBIT) announced the first patient was enrolled in a clinical study evaluating bermekimab therapy in adults with systemic sclerosis (SSc), otherwise known as scleroderma, a devastating inflammatory syndrome characterized by chronic...
Sep 27, 2019 08:15 am ET
XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain
XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb will be presenting clinical findings for bermekimab in the treatment of atopic dermatitis (AD) at the European Academy of Dermatology and Venereology (EADV) Congress being held in...
Sep 20, 2019 08:15 am ET
XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies
XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases. The patent describes studies...
Jul 11, 2019 08:30 am ET
Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis
XBiotech (NASDAQ: XBIT) announces that Seth Forman, M.D., will Chair the Company’s upcoming randomized, double-blind, placebo controlled Phase 2 study in Atopic Dermatitis (AD). This second Phase 2 study of bermekimab to treat moderate to severe AD...
Jul 10, 2019 08:00 am ET
XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board
XBiotech Inc. (NASDAQ: XBIT) announced today that Peter Libby, M.D., has been appointed to the Company’s Corporate Board of Directors.  Dr. Libby has played a pioneering role in discovering how inflammation leads to cardiovascular disease. Dr....
Jul 09, 2019 08:00 am ET
Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients
XBiotech (NASDAQ: XBIT) announced today that the Medical Research Council (MRC), part of UK Research and Innovation, has awarded funding to study bermekimab therapy in a Phase 2 multi-center study in advanced cancers. The MRC will provide funding...
Jun 26, 2019 08:30 am ET
XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas
XBiotech Inc. (NASDAQ: XBIT) announced today that it is the recipient of the first place 2019 Commercial Real Estate Award for Industrial Development, chosen by the Austin Business Journal. XBiotech USA Inc. received the award for its integrated...
Jun 25, 2019 08:45 am ET
XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and...
Jun 11, 2019 08:00 am ET
XBiotech Added to Russell 3000® Index
XBiotech Inc. (NASDAQ: XBIT) announced today that the Company has been added to the preliminary list of the broad market Russell 3000® Index, which will take effect after US market close on June 28, as part of the 2019 Russell indexes...
Jun 04, 2019 04:01 pm ET
XBiotech Announces Closing of Public Offering of Common Shares
XBiotech Inc. (NASDAQ: XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  In addition, XBiotech has granted the underwriter a...
May 31, 2019 08:47 am ET
XBiotech Announces Pricing of Public Offering of Common Shares
XBiotech Inc. (NASDAQ: XBIT) today announced the pricing of an underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  The offering is expected to close on or about June 4, 2019, subject to the...
May 30, 2019 04:32 pm ET
XBiotech Announces Public Offering of Common Shares
XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions.   XBiotech intends to grant the underwriter in the offering a 30-day option to purchase...
May 23, 2019 08:20 am ET
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa
XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe...
May 02, 2019 08:15 am ET
XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study
XBiotech Inc. (NASDAQ: XBIT) announced today enrollment of the final patient into its Phase I study1 evaluating bermekimab in patients with advanced pancreatic adenocarcinoma and cachexia. The study is being conducted and led by principal...
Apr 09, 2019 07:40 am ET
Research Report Identifies Net 1 UEPS Technologies, XBiotech, Rambus, Vector Group, Collectors Universe, and Gulf Island Fabrication with Renewed Outlook — Fundamental Analysis, Calculating Forward Mo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Net 1 UEPS Technologies, Inc. (NASDAQ:UEPS), XBiotech Inc. (NASDAQ:XBIT),...
Mar 05, 2019 08:15 am ET
Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
XBiotech (NASDAQ: XBIT) today released findings for its Phase 2 clinical study for bermekimab presented at the American Academy of Dermatology’s annual meeting which concluded today. Held at the Walter E. Washington Convention Center in Washington,...
Mar 01, 2019 11:44 am ET
Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting
XBiotech (NASDAQ: XBIT) announced today that breakthrough results from its Phase 2 clinical trial of its antibody therapy, bermekimab, are being presented tomorrow at a late-breaking oral presentation during the annual meeting of the American...
Jan 29, 2019 08:15 am ET
Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting
XBiotech (NASDAQ: XBIT) announced today that findings from its open label, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) will be presented at the “Late-Breaking Research: Clinical Trials” forum...
Jan 28, 2019 11:28 am ET
Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting
XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on...
Jan 23, 2019 08:30 am ET
Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain
XBiotech (NASDAQ: XBIT) announced today the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with moderate to severe Hidradenitis Suppurativa (HS).  Primary and key secondary endpoints were...
Dec 13, 2018 08:00 am ET
XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study
XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings on key biomarker analysis of colorectal cancer patients treated with bermekimab in its European Phase III study. The manuscript, entitled, “Interleukin-1 Receptor Antagonist...
Dec 12, 2018 08:30 am ET
XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease
XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints....
Dec 03, 2018 08:15 am ET
XBiotech Announces Successful Completion of GMP Audit
XBiotech Inc. (NASDAQ:XBIT) today announced a successful GMP (Good Manufacturing Practices) audit by Eurofins Amatsigroup. The audit was conducted in connection with XBiotech’s distribution in Europe of its US-manufactured biological drug product....
Nov 23, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jason Industries, Inc. (NASDAQ:JASN), XBiotech Inc. (NASDAQ:XBIT),...
Oct 31, 2018 04:05 pm ET
XBiotech Highlights Third Quarter Developments for 2018
XBiotech Inc. (NASDAQ: XBIT) today provided an update on recent company developments in its third quarter Form 10-Q filing with the SEC. The Company reports that it continues to make important progress in its clinical and pre-clinical programs in...
Oct 26, 2018 08:15 am ET
XBiotech Announces New Patents for Third Quarter 2018
XBiotech Inc. (NASDAQ: XBIT) announced today that it was awarded 11 new patents or patent allowances in the third quarter of 2018. Patents issued relate to the Company’s drug candidates bermekimab and 514G3, which target a crucial mediator of...
Oct 24, 2018 10:35 am ET
XBiotech Announces Dismissal of Securities Class Action Suit
XBiotech Inc. (NASDAQ: XBIT) announced today that the honorable Judge Dustin M. Howell of the 459th Travis County District Court has issued a letter ruling granting the Company’s Motion to Dismiss the securities class action complaint brought...
Oct 05, 2018 08:00 am ET
XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis
XBiotech Inc. (NASDAQ: XBIT) announced today that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis (AD). XBiotech has...
Sep 26, 2018 08:00 am ET
XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases
XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from...
Sep 24, 2018 08:30 am ET
XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa
XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa...
Sep 20, 2018 08:00 am ET
XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team
XBiotech Inc. (NASDAQ: XBIT) announced today the addition of Alice Gottlieb, M.D., Ph.D., to its Scientific Advisory Board (SAB).  Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of...
Sep 13, 2018 08:00 am ET
XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis
XBiotech Inc. (NASDAQ: XBIT) announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis (AD).  In the first phase of the study, 9 patients received a low dose (200mg/weekly) over a short course of treatment...
Sep 12, 2018 08:00 am ET
XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board
XBiotech Inc. (NASDAQ: XBIT) is pleased to announce the appointment of Peter Libby, MD to its Scientific Advisory Board (SAB). Dr. Libby will work with XBiotech to help further develop its clinical and research programs including studies evaluating...
Aug 27, 2018 08:00 am ET
XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks
XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings that point toward a white blood cell-derived interleukin-1 alpha (IL-1⍺) as a cause of blood clots that could lead to heart attacks or strokes. The research was headed by a...
Aug 10, 2018 08:00 am ET
XBiotech Highlights Quarterly Developments
XBiotech Inc. (NASDAQ: XBIT) provided an update on recent corporate and other developments in its Form 10-Q filing with the SEC. The Company reported, among other things, an approximately 50% reduction in operating expenses compared to the same...
Jul 10, 2018 08:00 am ET
XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa
XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating the Company’s subcutaneous formulation of MABp1 in patients with moderate to severe...
May 22, 2018 08:00 am ET
XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating MABp1 in patients with moderate to severe Atopic Dermatitis (AD). The patient began treatment...
Apr 16, 2018 08:00 am ET
XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology
XBiotech to Launch Two Phase 2 Clinical Studies to Study Subcutaneous Administration of MABp1 for Treatment of Hidradenitis Suppurativa and Atopic Dermatitis
Apr 02, 2018 08:00 am ET
XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
Agreement Centers on XBiotech’s Proprietary Manufacturing Technology to Advance Anti-NY-ESO-1 Antibody 12D7
Jan 26, 2018 08:00 am ET
XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Data Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) Provide Results that Corroborate HiSCR findings with iHS4 Scoring as a Measure of Efficacy
Jan 25, 2018 08:00 am ET
XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus
Report Documents 514G3’s Ability to Protect Mice Against Deadly S. aureus Bacteremia Infections
Jan 19, 2018 08:00 am ET
XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Open Label Extension Results, which Demonstrate Significant Improvements in HS Patients Previously Treated with Placebo, will be Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF)
Dec 11, 2017 11:18 am ET
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
The Klein Law Firm announces the commencement of an investigation of XBiotech, Inc. (NASDAQ: XBIT) concerning possible violations of federal securities laws. On April 20, 2017, XBiotech announced that the European Medicines Agency had rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech’s candidate antibody for the treatment of colorectal cancer. Then on May 18, 2017, XBiotech announced it had received a negative opinion for its MAA. Then on June 9, 2017, XBiotech a
Dec 04, 2017 08:00 am ET
XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative Dermatology
Report Highlights Efficacy of anti-IL-1 alpha Antibody Therapy in the Treatment of the Debilitating Skin Disease, Hidradenitis Suppurativa
Nov 17, 2017 03:39 pm ET
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
The Klein Law Firm announces the commencement of an investigation of XBiotech, Inc. (NASDAQ:XBIT) concerning possible violations of federal securities laws. On April 20, 2017, XBiotech announced that the European Medicines Agency had rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech’s candidate antibody for the treatment of colorectal cancer. Then on May 18, 2017, XBiotech announced it had received a negative opinion for its MAA. Then on June 9, 2017, XBiotech an
Nov 14, 2017 07:30 am ET
XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
IL-1a Neutralizing Antibody MABp1 Found to Block NETs’ Ability to Increase Endothelial Activation and Thrombogenicity
Nov 08, 2017 02:30 pm ET
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether XBiotech, Inc. (“XBiotech”) (NASDAQ:XBIT) violated federal securities laws.
Nov 03, 2017 11:54 am ET
XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary Thrombosis
Nov 03, 2017 09:36 am ET
XBIT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether XBiotech, Inc. (“XBiotech”) (NASDAQ: XBIT) violated federal securities laws.
Nov 02, 2017 04:42 pm ET
IMPORTANT XBIOTECH, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Western
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action  lawsuit  has been filed in the United States District Court for the Western District of Texas on behalf of investors who purchased  or otherwise  acquired shares  of XBiotech, Inc. (NASDAQ:XBIT) (the “Company”) between  April 15, 2015 and  April 20, 2017, inclusive (the “Class Period”)....
Sep 21, 2017 08:00 am ET
XBiotech to Present at Cantor Fitzgerald’s Global Healthcare Conference
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald’s Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company’s Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time....
Sep 20, 2017 08:00 am ET
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of OnivydeⓇ (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body...
Sep 07, 2017 08:00 am ET
XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
AUSTIN, Texas, Sept. 07, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from the investigator sponsored randomized Phase 2 study evaluating XBiotech’s True Human™ antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS) will be presented at the European Academy of Dermatology and Venereology (EADV) Congress in Geneva Switzerland. The oral presentation titled, “MABp1, a monoclonal antibody targeting interleukin 1 alpha in patients with hidradenitis suppurativa not eligible for adalimumab: results of a phase II randomized clinical trial” will be give...
May 16, 2017 06:22 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
NEW YORK, May 16, 2017 /PRNewswire/ -- Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. ("XBiotech") (NASDAQ: XBIT) concerning possible violations of federal securities laws. ...
Apr 21, 2017 06:48 pm ET
XBIOTECH NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm
NEW YORK, April 21, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at XBiotech, Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT)....
Apr 21, 2017 03:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, April 21, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Apr 20, 2017 06:48 pm ET
XBiotech Announces Outcome of EMA’s Oral Explanation Meeting
AUSTIN, Texas, April 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the European Medicines Agency (EMA) rendered a negative “trend” vote after meeting with the Company to discuss the “Day 180 List of Outstanding Issues” related to the Company’s marketing authorization application (MAA) for its candidate antibody for the treatment of colorectal cancer. A negative trend vote means it is unlikely that a positive Committee for Medicinal Products for Human Use (CHMP) opinion related to the Company’s MAA will be attained at the formal decision vote scheduled in May...
Mar 27, 2017 01:10 pm ET
XBiotech Announces On-Time Submission to the EMA
AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that it completed on time and confirmed receipt of its March 22, 2017 submission of responses to the remaining EMA queries related to its marketing authorization application. The Company feels confident it has addressed all outstanding issues raised in the application for its candidate antibody therapy for the treatment of colorectal cancer.   ...
Dec 07, 2016 08:00 am ET
XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer
AUSTIN, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized, double-blind, placebo-controlled Phase III study evaluating Xilonix as a treatment for advanced colorectal cancer. The Phase III study is being conducted under Fast Track designation from the FDA and involves over 600 advanced cancer patients from 18 countries world-wide. The Company reports that the first interim analysis allowing an assessment by the Data Monitoring Committee (DMC) of both safe...
Oct 12, 2016 09:10 am ET
XBiotech Announces Successful Completion of EMA GMP Inspection
AUSTIN, Texas, Oct. 12, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced a successful GMP (Good Manufacturing Practices) inspection by the European Medicines Agency (EMA). The EMA’s Competent Authorities of France [The French Agency for the Safety of Health Products], conducted the inspection in connection with the Xilonix Marketing Authorization Application. XBiotech’s production operations were deemed to be in general compliance with the principles and guidelines of good manufacturing practice as laid dow...
Oct 11, 2016 08:00 am ET
XBiotech Announces Dismissal of Class Action Lawsuit in Texas
AUSTIN, Texas, Oct. 11, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced that the U.S. District Court for the Western District of Texas granted the Company’s motion to dismiss in the 2015 securities class action lawsuit brought against the Company and certain of its directors. In a final judgment issued on October 7th, 2016, the Honorable Judge Sam Sparks dismissed the lawsuit with prejudice, meaning the plaintiff is barred from refiling the claim (Case 1:15-CV-1083-SS)....
Aug 22, 2016 03:05 pm ET
XBiotech Announces Grand Opening Date for New Commercial Manufacturing Facility
AUSTIN, Texas, Aug. 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced the timing for the grand opening of its state-of-the-art commercial manufacturing facility. The grand opening ceremony will take place on September 15, 2016 at 10 a.m. local time at the building’s location in Austin, Texas. It will include a ribbon-cutting ceremony, tour of the facility and a brief talk by XBiotech’s management....
Aug 10, 2016 08:00 am ET
XBiotech to Provide Second Quarter 2016 Business Update on August 16
AUSTIN, Texas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast on Tuesday, August 16, 2016, at 8:30 a.m. ET, to provide a quarterly overview for the second quarter ended June 30, 2016....
Jul 26, 2016 03:42 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of XBiotech, Inc. - XBIT
NEW YORK, July 26, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of XBiotech, Inc. (NASDAQGS: XBIT) ("XBiotech") concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.  ...
Jul 22, 2016 06:45 pm ET
XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU
AUSTIN, Texas, July 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, said today that the Independent Data Monitoring Committee (DMC) for the XCITE Phase III clinical study of Xilonix™ for the treatment of colorectal cancer, recently recommended study continuation without any amendment to the study design. The DMC convened as scheduled, subsequent to the enrollment of 400 patients into the study....
Jul 02, 2016 06:10 am ET
XBiotech Presents Pivotal Phase III Data Showing Xilonix™ Demonstrated Significant Clinical Response in Advanced Colorectal Cancer Patients Refractory to Further Treatment
Improved clinical response seen for multiple symptoms associated with disease progression and overall survival, with notable lack of toxicityXilonix is the first antibody therapy to neutralize biological activity of interleukin-1 alpha (IL-1α), a potent anti-inflammatory signaling molecule known to promote the growth and spread of tumorsXilonix granted accelerated review by the European Medicines Agency (EMA); an approval decision could come as early as fourth quarter 2016 AUSTIN, Texas, July 02, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human...
Jun 28, 2016 08:39 am ET
XBiotech Signs Agreement With Megapharm To Market Xilonix™ In Israel
AUSTIN, Texas, June 28, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, today announced that it has entered into an exclusive licensing agreement with Megapharm Ltd., to commercialize Xilonix™ in Israel for the treatment of advanced colorectal cancer....
Jun 08, 2016 11:11 am ET
XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company’s Extensive Product Portfolio
AUSTIN, Texas, June 08, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies, announced today that Trey Benson has joined the company as Commercial Head, effective June 6. Benson has more than two decades of global healthcare experience, with over 16 years of marketing and commercial development in the pharmaceutical industry, in both established and start-up organizations....
May 24, 2016 08:00 am ET
XBiotech to Present Positive Preliminary Survival Data on Xilonix™ at the 18th European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer
First Time Pivotal Phase III Xilonix Data to be Unveiled at Major Scientific Congress, Including Positive Preliminary Overall Mean Survival Data for RespondersDeveloped Specifically to Treat Advanced Cancer, Xilonix is First Antibody Therapy to Neutralize Biological Activity of Interleukin-1α (IL-1a)Xilonix Recently Granted Accelerated Review for Marketing Authorization by the European Medicines Agency (EMA); a decision on Xilonix approval could come as early as fourth quarter 2016 AUSTIN, Texas, May 24, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next generation Tr...
May 18, 2016 08:00 am ET
XBiotech Provides First Quarter 2016 Corporate and Clinical Update
Conference Call and Webcast today, May 18 at 8:30 a.m. ET...
May 16, 2016 08:00 am ET
XBiotech Names Industry Veteran Dawn McCollough to Head Clinical Operations
AUSTIN, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies, today announced that Dawn McCollough has joined the company as Vice President of Clinical Operations, effective May 16. McCollough has more than two decades of global industry experience and has overseen all phases of clinical trial drug development across multiple therapeutic areas....
May 11, 2016 08:00 am ET
XBiotech to Provide First Quarter 2016 Business Update on May 18
AUSTIN, Texas, May 11, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast on Wednesday, May 18, 2016, at 8:30 a.m. ET, to provide a quarterly overview for the first quarter ended March 31, 2016....
Jan 25, 2016 04:43 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving XBiotech Inc. and a Lead Plaintiff Deadline of February 1, 2016 -- XBIT
NEW YORK, Jan. 25, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Texas on behalf of investors who purchased XBiotech Inc. (Nasdaq: XBIT) securities between April 15, 2015 and November 23, 2015....
Jan 21, 2016 09:05 pm ET
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of XBiotech Inc. - XBIT
BALA CYNWYD, Pa., Jan. 21, 2016 /PRNewswire/ -- Law Office of Brodsky & Smith, LLC announces an investigation of XBiotech Inc. ("XBiotech" or the "Company") (Nasdaq -XBIT- News) for potential violations of federal securities laws and breaches of the XBiotech Board's fiduciary duties. ...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.